ANNUAL INFLAMMASOME SUMMIT UNITES WORLD RENOWNED EXPERTS IN INFLAMMASOME-TARGETED DRUG DEVELOPMENT AND ACADEMIA TO SHARE INFORMATION AND ADDRESS KNOWLEDGE GAPS IN THIS RAPIDLY EVOLVING FIELD ZYVERSA IS WELL POSITIONED IN THE EMERGING INFLAMMASOME SPACE WITH A HIGHLY DIFFERENTIATED INFLAMMASOME ASC

ANNUAL INFLAMMASOME SUMMIT UNITES WORLD RENOWNED EXPERTS IN INFLAMMASOME-TARGETED DRUG DEVELOPMENT AND ACADEMIA TO SHARE INFORMATION AND ADDRESS KNOWLEDGE GAPS IN THIS RAPIDLY EVOLVING FIELD ZYVERSA IS WELL POSITIONED IN THE EMERGING INFLAMMASOME SPACE WITH A HIGHLY DIFFERENTIATED INFLAMMASOME ASC

ZYVERSA IS WELL POSITIONED IN THE RAPIDLY EMERGING INFLAMMASOME SPACE WITH A HIGHLY DIFFERENTIATED INFLAMMASOME ASC INHIBITOR, IC 100, WHICH HAS POTENTIAL TO TREAT A BROAD RANGE OF INFLAMMATORY DISEASES ZYVERSA'S PIPELINE INCLUDES VAR 200, A PHASE 2A-READY FIRST-IN-CLASS CHOLESTEROL EFFLUX MEDIATOR